Cargando…

Outcomes of Isocitrate Dehydrogenase Wild Type Glioblastoma after Re-irradiation

PURPOSE: Glioblastomas (GBM) are the most common malignant primary brain tumors in adults and have a dismal prognosis. Patients frequently suffer from local tumor recurrences, with limited therapeutic options. Re-irradiation represents a possible intervention, but given the recent 5th edition of the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ehret, Felix, Wolfgang, Josy, Allwohn, Luisa, Onken, Julia, Wasilewski, David, Roohani, Siyer, Oertel, Joachim, Zips, Daniel, Kaul, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10369398/ https://www.ncbi.nlm.nih.gov/pubmed/37502699 http://dx.doi.org/10.1016/j.ctro.2023.100653

Ejemplares similares

Treating oligodendroglioma – An analysis of a homogeneous 1p/19q-codeleted and isocitrate dehydrogenase-mutant patient cohort
por: Allwohn, Luisa, et al.
Publicado: (2023)

Wild-type isocitrate dehydrogenase under the spotlight in glioblastoma
por: Alzial, Gabriel, et al.
Publicado: (2021)

Sarcoma classification by DNA methylation profiling in clinical everyday life: the Charité experience
por: Roohani, Siyer, et al.
Publicado: (2022)

Photon and Proton irradiation in Patient-derived, Three-Dimensional Soft Tissue Sarcoma Models
por: Roohani, Siyer, et al.
Publicado: (2023)

An independently validated nomogram for isocitrate dehydrogenase-wild-type glioblastoma patient survival
por: Gittleman, Haley, et al.
Publicado: (2019)

Effect of Levetiracetam Use Duration on Overall Survival of Isocitrate Dehydrogenase Wild-Type Glioblastoma in Adults
por: King-Stephens, David
Publicado: (2022)

A Case of Glioblastoma, Isocitrate Dehydrogenase Wild Type, With Widely Disseminated Osseous Metastasis
por: Conte, Brianna, et al.
Publicado: (2022)

The T2-FLAIR mismatch sign in glioblastoma, isocitrate dehydrogenase wild-type A case report
por: Nishimura, Shunsuke, et al.
Publicado: (2023)

Patterns of Failure in High-Grade Soft Tissue Sarcomas of the Extremities and Trunk Wall After Pre- or Postoperative Radiation Therapy
por: Roohani, Siyer, et al.
Publicado: (2023)

Mismatch repair protein mutations in isocitrate dehydrogenase (IDH)-mutant astrocytoma and IDH-wild-type glioblastoma
por: Richardson, Timothy E, et al.
Publicado: (2023)

Radiomic model for predicting mutations in the isocitrate dehydrogenase gene in glioblastomas
por: Hsieh, Kevin Li-Chun, et al.
Publicado: (2017)

Integrated pharmaco-proteogenomics defines two subgroups in isocitrate dehydrogenase wild-type glioblastoma with prognostic and therapeutic opportunities
por: Oh, Sejin, et al.
Publicado: (2020)

Preoperative Predictors of Early Mortality Risk in Isocitrate Dehydrogenase-Wild-Type Glioblastoma Patients Treated with Standard Therapy
por: Zhao, Chao, et al.
Publicado: (2021)

Diffuse paediatric-type high-grade glioma, H3-wildtype and IDH-wildtype: case series of a new entity
por: Bender, Katja, et al.
Publicado: (2023)

Expression of Cathepsins B, D, and G in Isocitrate Dehydrogenase-Wildtype Glioblastoma
por: Koh, Sabrina P., et al.
Publicado: (2017)

Radiomics Analysis Based on Magnetic Resonance Imaging for Preoperative Overall Survival Prediction in Isocitrate Dehydrogenase Wild-Type Glioblastoma
por: Wang, Shouchao, et al.
Publicado: (2022)

Isocitrate Dehydrogenase (IDH)1/2 Mutations as Prognostic Markers in Patients With Glioblastomas
por: Chen, Jun-Rui, et al.
Publicado: (2016)

Computer-aided diagnosis of isocitrate dehydrogenase genotypes in glioblastomas from radiomic patterns
por: Lo, Chung-Ming, et al.
Publicado: (2020)

A novel isocitrate dehydrogenase 1 G131D mutation in glioblastoma
por: Wang, Lei-Ming, et al.
Publicado: (2021)

Clinical implications of hypoxia-inducible factor-1α and caveolin-1 overexpression in isocitrate dehydrogenase-wild type glioblastoma multiforme
por: Chen, Wenli, et al.
Publicado: (2019)

Distinguishing Pseudoprogression From True Early Progression in Isocitrate Dehydrogenase Wild-Type Glioblastoma by Interrogating Clinical, Radiological, and Molecular Features
por: Li, Mingxiao, et al.
Publicado: (2021)

Favorable prognostic impact of phosphatase and tensin homolog alterations in wild-type isocitrate dehydrogenase and telomerase reverse transcriptase promoter glioblastoma
por: Higa, Nayuta, et al.
Publicado: (2023)

Isocitrate Dehydrogenase-1 Mutations as Prognostic Biomarker in Glioblastoma Multiforme Patients in West Bohemia
por: Polivka, J., et al.
Publicado: (2014)

Corrigendum: Distinguishing Pseudoprogression From True Early Progression in Isocitrate Dehydrogenase Wild-Type Glioblastoma by Interrogating Clinical, Radiological and Molecular Features
por: Li, Mingxiao, et al.
Publicado: (2021)

Isocitrate dehydrogenase mutations in myeloid malignancies
por: Medeiros, B C, et al.
Publicado: (2017)

The prognostic significance of wild-type isocitrate dehydrogenase 2 (IDH2) in breast cancer
por: Aljohani, Abrar I., et al.
Publicado: (2019)

Mutation of Isocitrate Dehydrogenase 1 in Cholangiocarcinoma Impairs Tumor Progression by Inhibiting Isocitrate Metabolism
por: Su, Li, et al.
Publicado: (2020)

Oncogenic transgelin-2 is differentially regulated in isocitrate dehydrogenase wild-type vs. mutant gliomas
por: Beyer, Sasha J., et al.
Publicado: (2018)

Wild-Type Isocitrate Dehydrogenase-Dependent Oxidative Decarboxylation and Reductive Carboxylation in Cancer and Their Clinical Significance
por: He, Qiwei, et al.
Publicado: (2022)

Isocitrate dehydrogenase inhibitors in acute myeloid leukemia
por: Liu, Xiaoyan, et al.
Publicado: (2019)

The Role of Isocitrate Dehydrogenases in Direct Reprogramming to Cardiomyocytes
por: Ishida, Tomoaki, et al.
Publicado: (2021)

Isocitrate dehydrogenase 1 (IDH1) mutation-specific microRNA signature predicts favorable prognosis in glioblastoma patients with IDH1 wild type
por: Wang, Zheng, et al.
Publicado: (2013)

U3 snoRNA‐mediated degradation of ZBTB7A regulates aerobic glycolysis in isocitrate dehydrogenase 1 wild‐type glioblastoma cells
por: Dong, Weiwei, et al.
Publicado: (2023)

Mutations in Isocitrate Dehydrogenase 1 and 2 Occur Frequently in Intrahepatic Cholangiocarcinomas and Share Hypermethylation Targets with Glioblastomas
por: Wang, Pu, et al.
Publicado: (2012)

Association of Isocitrate Dehydrogenase (IDH) Status With Edema to Tumor Ratio and Its Correlation With Immune Infiltration in Glioblastoma
por: Dubinski, Daniel, et al.
Publicado: (2021)

Development of a novel glycolysis-related genes signature for isocitrate dehydrogenase 1-associated glioblastoma multiforme
por: Cai, Xiaomin, et al.
Publicado: (2022)

Importance of Age and Noncontrast-Enhancing Tumor as Biomarkers for Isocitrate Dehydrogenase–Mutant Glioblastoma: A Multicenter Study
por: Uetani, Hiroyuki, et al.
Publicado: (2023)

TERT Mutation Is Accompanied by Neutrophil Infiltration and Contributes to Poor Survival in Isocitrate Dehydrogenase Wild-Type Glioma
por: Gao, Mengqi, et al.
Publicado: (2021)

Profiling the Effect of Targeting Wild Isocitrate Dehydrogenase 1 (IDH1) on the Cellular Metabolome of Leukemic Cells
por: Shait Mohammed, Mohammed Razeeth, et al.
Publicado: (2022)

Preoperative hypofractionated radiotherapy for soft tissue sarcomas: a systematic review
por: Roohani, Siyer, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9bm3l6v8c7j47d9eb5g8jbg2i6